News | May 18, 2021
Remdesivir production increased to 119 lakh vials per month
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
